Answers are grounded in this paper and cite their sources.
Background Pathological scars are characterized by persistent fibroblast activation and excessive extracellular matrix deposition, but the spatial organization of fibroblast populations and the immune signals driving their remodeling remain unclear. Methods We integrated single-cell RNA sequencing, spatial transcriptomics, bulk RNA sequencing, targeted energy metabolomics, Mendelian randomization, CUT&Tag analysis, validation studies using human tissue, primary cell functional assays, and experiments involving two mouse models to investigate fibroblast-state remodeling in pathological scars. Ligand–receptor analysis and macrophage-conditioned medium experiments were used to evaluate the regulation of immune–stromal populations. Results The proportion of PI16+ fibroblasts was reduced in pathological scars, and these cells were preferentially localized to adjacent dermis and the scar border; on the other hand, POSTN+ fibroblasts accumulated in extracellular matrix- and TGF-β-rich scar cores. PI16 loss promoted fibroblast proliferation, migration, contraction, glycolytic activation, and profibrotic remodeling, which were accompanied by increased POSTN expression. Perturbation of CAV1 expression altered macrophage PDGF-BB secretion, whereas PDGF-BB signaling activated PDGFRB–PI3K/AKT–RUNX2 signaling in fibroblasts. RUNX2 directly occupied regulatory regions of ENO1, PKM, and LDHA and promoted glycolytic reprogramming. Blocking PDGF-BB signaling, PI3K/AKT or RUNX2 activity or glycolysis attenuated profibrotic fibroblast functions. AAV9-mediated restoration of PI16 expression reduced dermal fibrosis, collagen deposition, glycolytic activation, and scar formation in mice. Conclusion Pathological scar progression is characterized by spatially organized PI16+/POSTN+ fibroblast-state remodeling. Macrophage-derived PDGF-BB signaling and RUNX2-dependent glycolytic reprogramming are linked to this remodeling process, indicating that restoring the expression of PI16 and inhibiting the PDGF-BB–RUNX2–glycolysis axis may represent a potential therapeutic strategy.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: